Literature DB >> 27020784

Effects of prazosin and doxazosin on yohimbine-induced reinstatement of alcohol seeking in rats.

D Funk1, K Coen2, S Tamadon2, Z Li2, A Loughlin2, A D Lê2,3,4.   

Abstract

RATIONALE AND
OBJECTIVES: Alpha-1 adrenoceptor antagonists, such as prazosin, show promise in treating alcoholism. In rats, prazosin reduces alcohol self-administration and relapse induced by footshock stress and the alpha-2 antagonist yohimbine, but the processes involved in these effects of prazosin are not known. Here, we present studies on the central mechanisms underlying the effects of prazosin on yohimbine-induced reinstatement of alcohol seeking.
METHODS: In experiment 1, we trained rats to self-administer alcohol (12 % w/v, 1 h/day), extinguished their responding, and tested the effects of prazosin, administered ICV (2 and 6 nmol) or systemically (1 mg/kg) on yohimbine (1.25 mg/kg)-induced reinstatement. In experiment 2, we determined potential central sites of action by analyzing effects of prazosin (1 mg/kg) on yohimbine (1.25 mg/kg)-induced Fos expression. In experiment 3, we determined the effects of doxazosin (1.25, 2.5, and 5 mg/kg), an alpha-1 antagonist with a longer half-life on yohimbine-induced reinstatement.
RESULTS: Yohimbine-induced reinstatement of alcohol seeking was reduced significantly by ICV and systemic prazosin (50 and 69 % decreases, respectively). Systemic prazosin reduced yohimbine-induced Fos expression in the prefrontal cortex, accumbens shell, ventral bed nucleus of the stria terminalis, and basolateral amygdala (46-67 % decreases). Doxazosin reduced yohimbine-induced reinstatement of alcohol seeking (78 % decrease).
CONCLUSIONS: Prazosin acts centrally to reduce yohimbine-induced alcohol seeking. The Fos mapping study suggests candidate sites where it may act. Doxazosin is also effective in reducing yohimbine-induced reinstatement. These data provide information on the mechanisms of alpha-1 antagonists on yohimbine-induced alcohol seeking and indicate their further investigation for the treatment of alcoholism.

Entities:  

Keywords:  Alcohol self-administration; Alpha-1 adrenoceptors; Fos; Noradrenaline; Relapse; Stress

Mesh:

Substances:

Year:  2016        PMID: 27020784     DOI: 10.1007/s00213-016-4273-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  79 in total

Review 1.  Brain circuitry and the reinstatement of cocaine-seeking behavior.

Authors:  Peter W Kalivas; Krista McFarland
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

2.  Antagonism of lateral amygdala alpha1-adrenergic receptors facilitates fear conditioning and long-term potentiation.

Authors:  Stephanie C Lazzaro; Mian Hou; Catarina Cunha; Joseph E LeDoux; Christopher K Cain
Journal:  Learn Mem       Date:  2010-09-24       Impact factor: 2.460

3.  Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Authors:  Janice C Froehlich; Brett Hausauer; Stephen Fischer; Bradley Wise; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2015-08       Impact factor: 3.455

4.  A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.

Authors:  Tracy L Simpson; Carol A Malte; Bergetta Dietel; Dana Tell; Ian Pocock; Robert Lyons; Dana Varon; Murray Raskind; Andrew J Saxon
Journal:  Alcohol Clin Exp Res       Date:  2015-04-01       Impact factor: 3.455

5.  Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.

Authors:  M J Millan; A Newman-Tancredi; V Audinot; D Cussac; F Lejeune; J P Nicolas; F Cogé; J P Galizzi; J A Boutin; J M Rivet; A Dekeyne; A Gobert
Journal:  Synapse       Date:  2000-02       Impact factor: 2.562

6.  Pharmacological blockade of corticotropin-releasing hormone receptor 1 (CRH1R) reduces voluntary consumption of high alcohol concentrations in non-dependent Wistar rats.

Authors:  Andrea Cippitelli; Ruslan Damadzic; Erick Singley; Annika Thorsell; Roberto Ciccocioppo; Robert L Eskay; Markus Heilig
Journal:  Pharmacol Biochem Behav       Date:  2011-10-20       Impact factor: 3.533

7.  Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats.

Authors:  A D Lê; Douglas Funk; Kathleen Coen; Zhaoxia Li; Yavin Shaham
Journal:  Addict Biol       Date:  2011-10-04       Impact factor: 4.280

8.  The α1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats.

Authors:  Meghan L O'Neil; Lauren E Beckwith; Carrie L Kincaid; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2012-07-03       Impact factor: 3.455

9.  Tissue distribution and hypotensive effect of prazosin in the conscious rat.

Authors:  M K Dynon; B Jarrott; W J Louis
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

Review 10.  Neurobiology of relapse to alcohol in rats.

Authors:  A Lê; Y Shaham
Journal:  Pharmacol Ther       Date:  2002 Apr-May       Impact factor: 12.310

View more
  20 in total

1.  Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Authors:  Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker
Journal:  Alcohol       Date:  2020-07-24       Impact factor: 2.405

Review 2.  Noradrenergic targets for the treatment of alcohol use disorder.

Authors:  Carolina L Haass-Koffler; Robert M Swift; Lorenzo Leggio
Journal:  Psychopharmacology (Berl)       Date:  2018-02-20       Impact factor: 4.530

Review 3.  Probing for Neuroadaptations to Unpredictable Stressors in Addiction: Translational Methods and Emerging Evidence.

Authors:  Jesse T Kaye; Daniel E Bradford; Katherine P Magruder; John J Curtin
Journal:  J Stud Alcohol Drugs       Date:  2017-05       Impact factor: 2.582

4.  Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder.

Authors:  Terril L Verplaetse; Elizabeth Ralevski; Walter Roberts; Ralitza Gueorguieva; Sherry A McKee; Ismene L Petrakis
Journal:  Alcohol Clin Exp Res       Date:  2019-02-19       Impact factor: 3.455

5.  Central Noradrenergic Interactions with Alcohol and Regulation of Alcohol-Related Behaviors.

Authors:  Elena M Vazey; Carolina R den Hartog; David E Moorman
Journal:  Handb Exp Pharmacol       Date:  2018

6.  Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder.

Authors:  Tracy L Simpson; Andrew J Saxon; Cynthia Stappenbeck; Carol A Malte; Robert Lyons; Dana Tell; Steven P Millard; Murray Raskind
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

Review 7.  Behavioral, neurobiological, and neurochemical mechanisms of ethanol self-administration: A translational review.

Authors:  Ashley A Vena; Shannon L Zandy; Roberto U Cofresí; Rueben A Gonzales
Journal:  Pharmacol Ther       Date:  2020-05-11       Impact factor: 12.310

8.  Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol.

Authors:  Carolina R den Hartog; Katrina L Blandino; McKenzie L Nash; Emily R Sjogren; Michael A Grampetro; David E Moorman; Elena M Vazey
Journal:  Psychopharmacology (Berl)       Date:  2020-06-25       Impact factor: 4.530

9.  Central amygdala relaxin-3/relaxin family peptide receptor 3 signalling modulates alcohol seeking in rats.

Authors:  Leigh C Walker; Hanna E Kastman; Elena V Krstew; Andrew L Gundlach; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

Review 10.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.